Research peptides · For laboratory and scientific research in vitro · Not medications · Not approved for consumption · Adults only (18+)
Tesamorelin
In plain language
Tesamorelin is the -approved analog (Egrifta), known for its unique selectivity toward visceral adipose tissue. Clinical trials document 15-18% reduction of internal-organ fat without affecting subcutaneous tissue.
For researchers
Tesamorelin is a stabilized synthetic analog of human hypothalamic (growth hormone-releasing hormone), modified with a trans-3-hexenoyl group at the N-terminus to resist dipeptidyl peptidase IV (DPP-IV). It stimulates the anterior pituitary to secrete endogenous growth hormone in natural pulses without bypassing physiological feedback mechanisms — the fundamental difference from recombinant . Under the trade name Egrifta it was approved by the in 2010 for treatment of excess visceral adipose tissue in HIV-associated lipodystrophy, following Theratechnologies clinical trials (Falutz et al., NEJM 2007). Documented reduction averages 15-18% of visceral fat volume over 26 weeks, with no significant effect on subcutaneous fat. Half-life ~26 minutes via subcutaneous administration. In modern research protocols it is studied for metabolic syndrome, NAFLD (non-alcoholic fatty liver disease) and cardiovascular risk. Standard research dose is 1-2 mg s.c. daily. Storage: -20°C lyophilized; reconstituted solution stable 7 days at 2-8°C.
Scientific literature
Other peptides
Information about Tesamorelin is based on published scientific research and is intended for research purposes. Not medical advice.
Products related to this peptide are for in vitro laboratory research only. Not approved for human consumption.